Can glycopyrrolate replace temporary pacemaker and atropine in patients at high risk for symptomatic bradycardia undergoing AngioJet mechanical thrombectomy?

Abstract

We studied the feasibility and efficacy of glycopyrrolate, a synthetic anticholinergic agent with shorter half-life and without reflex tachycardia, in preventing symptomatic bradycardia in patients undergoing mechanical thrombectomy with the AngioJet Rheolytic Thrombectomy System (Possis Medical, Inc., Minneapolis, Minnesota). There was no need for temporary pacemaker insertion and no hemodynamically significant bradycardia in 10 consecutive patients. Additionally, there were no adverse effects from glycopyrrolate therapy. Our pilot study demonstrates that glycopyrrolate may replace temporary pacemaker insertion in these patients at high risk for symptomatic bradycardia.

• Authors: Tariqshah Syed, Jacqueline Tamis-Holland, David Coven, Mun K Hong
• Journal: The Journal of invasive cardiology (J Invasive Cardiol) Vol. 20 Issue 8 Suppl A Pg. 19A-21A (Aug 2008) ISSN: 1557-2501 [Electronic] United States
• PMID: 18830018 (Publication Type: Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Muscarinic Antagonists
• Atropine
• Glycopyrrolate

Topics

• Anti-Arrhythmia Agents (administration & dosage)
• Atropine (administration & dosage)
• Bradycardia (drug therapy, etiology, prevention & control)
• Cardiac Catheterization (adverse effects)
• Coronary Thrombosis (therapy)
• Feasibility Studies
• Female
• Glycopyrrolate (adverse effects)
• Humans
• Male
• Muscarinic Antagonists (therapeutic use)
• Pacemaker, Artificial
• Pilot Projects
• Thrombectomy (adverse effects)
• Time Factors